Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Lung Cancer treatment details. Biologic therapy. National Kyushu Cancer Center, Fukuoka, Japan



Survival: 11.5 months
   
Toxicity Grade: 5
   
Treatments: Biologic therapy
   
Drugs:
Country: Japan
   
City/State/Province: Fukuoka
   
Hospital: National Kyushu Cancer Center
   
Journal: Link
   
Date: 9/2008

Description:
Patients: This phase III study involved 489 patients with non-small cell lung cancer. The majority (about 62%) were men. About 44% were 65 years of age or older.

Treatment: Patients were treated with either gefitinib or docetaxel. Gefitinib is a biological therapy, and docetaxel is a chemotherapy.

Toxicity: Four patients died while on this study, all in the group being treated with gefitinib. These deaths were from interstitial lung disease and pneumonia. More patients treated with docetaxel experienced grade 3 and 4 toxicities. The most common toxicities in patients treated with gefitinib were rash/acne, and diarrhea, and neutropenia and alopecia in patients treated with docetaxel.

Results: The median overall survival was 11.5 months for patients treated with gefitinib.

Support: This study was supported by AstraZeneca, which markets gefitinib as Iressa.

Correspondence: Dr. Yukito Ichinose

E-mail to a Friend Email Physician More Information